Medicine talks in averages, but patients live in individual outcomes, and the gap between the two is wider than most clinical conversations admit. Two people with the same diagnosis and the same treatment can have radically different trajectories, and the reasons for that variability are only partially understood. Acknowledging the gap honestly would change how patients evaluate decisions and how doctors communicate uncertainty.
Genetic and biological variability is enormous
The Human Genome Project and the pharmacogenomics research that followed have demonstrated that drug metabolism, immune response, and disease progression vary substantially based on genetic differences that aren’t captured in routine clinical care. CYP450 enzyme variants alone affect how patients metabolize roughly a quarter of commonly prescribed drugs, with some patients clearing medications so quickly they get no effect and others so slowly they experience toxicity at standard doses. This is one variable among hundreds. Tumor genetics, microbiome composition, and immune profiles all introduce variability that average-based clinical guidelines smooth over. When a doctor says a treatment “works in 70 percent of cases,” that statistic obscures whether you happen to be in the responder group or the non-responder group, and current clinical practice often can’t tell you in advance.
Social and behavioral factors compound the variability
Medical outcomes also depend heavily on factors outside the clinic. Adherence to medication regimens varies enormously, with studies showing 30 to 50 percent of prescriptions either unfilled or taken inconsistently within months. Diet, exercise, sleep, stress, and social support all interact with treatment in ways that clinical trials struggle to control for. A patient with strong social support, stable housing, and adequate income often outperforms the trial average for almost any chronic condition; a patient without those resources often underperforms it, regardless of which medication they’re taking. Healthcare systems collect very little of this data systematically, which means clinical decisions are made on a narrower information set than the actual outcomes depend on.
Why averages mislead in practice
When a treatment is described as having a 60 percent success rate, patients often interpret this as “I have a 60 percent chance of success.” That’s not what it means. The 60 percent reflects the proportion of patients in the trial population who responded, and the trial population may not resemble you. If responders share characteristics, certain genotypes, certain disease subtypes, certain comorbidities, then your individual probability could be 90 percent or 10 percent depending on which group you fall into. Modern oncology has begun explicitly stratifying patients this way, and survival statistics for many cancers now look very different when reported by molecular subtype rather than by tumor location alone. Most of medicine hasn’t caught up yet, but the conceptual move is the same: averages describe populations, not individuals.
The bottom line
Variability in health outcomes isn’t a flaw in medicine; it’s a feature of biology that medicine is gradually learning to accommodate. The honest conversation with a doctor includes asking what’s known about your specific subtype, what factors predict response, and what the range of outcomes looks like rather than just the mean. Patients who ask these questions get better information. The averages are a starting point. They were never meant to be the answer.
Leave a Reply